Pulmonary mucus: Pediatric perspective

Pediatric Pulmonology

Volumn 36, Issue 3, 2003, Pages 178-188

  Rogers, Duncan F ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Airway; Asthma; Children; Lung; Mucin; Recurrent bronchitis; Respiratory tract

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ACETYLCYSTEINE; AG 1571; ANTISENSE OLIGONUCLEOTIDE; BUTIXICORT; CAPSAZEPINE; CHLORIDE CHANNEL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CYTOKINE; DEOXYRIBONUCLEASE; DIQUAFOSOL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EXPECTORANT AGENT; FLUNISOLIDE; FLUTICASONE; GEFITINIB; GLUCOCORTICOID; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MARCKS PROTEIN; MOMETASONE FUROATE; MONTELUKAST; MSI 1956; MUCIN; MUCOLYTIC AGENT; ODN 64; ODN 83; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SUPLATAST TOSYLATE; TACHYKININ RECEPTOR ANTAGONIST; TIOTROPIUM BROMIDE; TIPREDANE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST;

ADULT; AIRWAY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHITIS; CHILD; DRUG DELIVERY SYSTEM; GOBLET CELL; HUMAN; INFLAMMATION; INFLAMMATORY CELL; INHALER; LUNG; MUCUS; MUCUS GLAND; MUCUS SECRETION; PATHOPHYSIOLOGY; PEDIATRICS; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; SIDE EFFECT;

ADULT; AGE FACTORS; ANTIOXIDANTS; ASTHMA; BRONCHITIS; CHILD; CHOLINERGIC ANTAGONISTS; CYTOKINES; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUCUS; PROTEASE INHIBITORS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RESPIRATORY PHYSIOLOGY;

EID: 0041854463     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.10322     Document Type: Review

References (110)

1. Davidson KL. Airway clearance strategies for the pediatric patient. Respir Care 2002;47:823-828.
2. Wood RA. Pediatric asthma. JAMA 2002;288:745-747.
3. Gaillard D, Jouet JB, Egreteau L, et al. Airway epithelial damage and inflammation in children with recurrent bronchitis. Am J Respir Crit Care Med 1994;150:810-817.
4. Liu YC, Khawaja AM, Rogers DE Pathophysiogy of airway mucus secretion in asthma. In: Barnes PJ, Rodger IW, Thomson NC, editors. Asthma. Basic mechanisms and clinical management. London: Academic Press; 1998. p 205-227.
5. Rogers DE Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis 2000;55:324-332.
6. Davies JR, Herrmann A, Russell W, Svitacheva N, Wickström C, Carlstedt I. Respiratory tract mucins: structure and expression patterns. Mucus hypersecretion in respiratory disease. Chichester: John Wiley & Sons; 2002.
7. Davis PB. Cystic fibrosis. Pediatr Rev 2001;22:257-264.
8. Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest 2002;109:571-577.
9. Voynow JA. What does mucin have to do with lung disease? Paediatr Respir Rev 2002;3:98-103.
10. Widdicombe JH, Widdicombe JG. Regulation of human airway surface liquid. Respir Physiol 1995;99:3-12.
11. Smith JJ, Travis SM, Greenberg EP, Welsh MJ. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85:229-236.
12. Gallo RL, Murakami M, Ohtake T. Zaiou M. Biology and clinical relevance of naturally occurring antimicrobial peptides. J Allergy Clin Immunol 2002;110:823-831.
13. Teramoto S, Mastsue T, Ouchi Y. Manipulation of volume vs. osmolality in cystic fibrosis lung disease. Chest 1999;116:1494-1495.
14. Rogers DF. The airway goblet cell. Int J Biochem Cell Biol 2003;35:1-6.
15. Finkbeiner WE. Physiology and pathology of tracheobronchial glands. Respir Physiol 1999;118:77-83.
16. Lapensee L, Paquette Y, Bleau G. Allelic polymorphism and chromosomal localization of the human oviductin gene (MUC9). Fertil Steril 1997;68:702-708.
17. Wu GJ. Wu MW, Wang SW, et al. Isolation and characterization of the major form of human MUC 18 cDNA gene and correlation of MUC18 over-expression in prostate cancer cell lines and tissues with malignant progression. Gene 2001;279:17-31.
18. Dekker J, Rossen JW, Buller HA, Einerhand AW. The MUC family: an obituary. Trends Biochem Sci 2002;27:126-131.
19. Gum JR Jr, Crawley SC, Hicks JW, Szymkowski DE, Kim YS. MUC17, a novel membrane-tethered mucin. Biochem Biophys Res Commun 2002;291:466-475.
20. Copin MC, Buisine MP. Devisme L, et al. Normal respiratory mucosa, precursor lesions and lung carcinomas: differential expression of human mucin genes. Front Biosci 2001;6:1264-1275.
21. Lamb D. The histochemical type of glycoprotein produced by mucous cells of normal and diseased bronchi in childhood. J Pathol 1971;103:3.
22. Hovenberg HW, Davies JR, Herrmann A, Linden CJ, Carlstedt I. MUC5AC, but not MUC2, is a prominent mucin in respiratory secretions. Glycoconj J 1996;13:839-847.
23. Thornton DJ, Carlstedt I, Howard M, Devine PL, Price MR, Sheehan JK. Respiratory mucins: identification of core proteins and glycoforms. Biochem J 1996;316:967-975.
24. Kirkham S, Sheehan JK, Knight D, Richardson PS, Thornton DJ. Heterogeneity of airways mucus: variations in the amounts and glycoforms of the major oligomeric mucins MUC5AC and MUC5B. Biochem J 2002;361:537-546.
25. Thornton DJ, Davies JR, Kraayenbrink M, Richardson PS, Sheehan JK, Carlstedt I. Mucus glycoproteins from "normal" human tracheobronchial secretion. Biochem J 1990;265:179-186.
26. Thornton DJ, Devine PL, Hanski C, Howard M, Sheehan JK. Identification of two major populations of mucins in respiratory secretions. Am J Respir Crit Care Med 1994;150:823-832.
27. Davies JR, Hovenberg HW, Linden CJ, et al. Mucins in airway secretions from healthy and chronic bronchitic subjects. Biochem J 1996;313:431-439.
28. National Institutes of Health. Global initiative for asthma: pocket guide for asthma management and prevention. Publication no. 02-3659. Bethesda, MD: National Institutes of Health. National Heart, Lung and Blood Institute; 2002.
29. British Thoracic Society and Scottish Intercollegiate Network. British guideline on the management of asthma. Thorax [Suppl] 2003;58:1-94.
30. Eapen SS, Busse WW. Asthma. Clin Allergy Immunol 2002;16:325-353.
31. Rogers DF, Evans TW. Plasma exudation and oedema in asthma. Br Med Bull 1992;48:120-134.
32. Dunnill MS. The pathology of asthma with special reference to changes in the bronchial mucosa. J Clin Pathol 1960;13:27-33.
33. Saetta M, Di Stefano A, Rosina C, Thiene G, Fabbri LM. Quantitative structural analysis of peripheral airways and arteries in sudden fatal asthma. Am Rev Respir Dis 1991;143:138-143.
34. Cutz E, Levison H, Cooper DM. Ultrastructure of airways in children with asthma. Histopathology 1978;2:407-421.
35. Maxwell GM. The problem of mucus plugging in children with asthma. J Asthma 1985;22:131-137.
36. Bowen A, Oudjhane K, Odagiri K, Liston SL, Cumming WA, Oh KS. Plastic bronchitis: large, branching, mucoid bronchial casts in children. AJR 1985;144:371-375.
37. Bettmann M. Report of a case of fibrinous bronchitis, with a review of all cases in the literature. Am J Med Sci 1902;123:304-329.
38. Sanerkin G, Seal RE, Leopold JG. Plastic bronchitis, mucoid impaction of the bronchi and allergic bronchopulmonary aspergillosis, and their relationship to bronchial asthma. Ann Allergy 1966;24:586-594.
39. Morgan AD, Bogomoletz W. Mucoid impaction of the bronchi in relation to asthma and plastic bronchitis. Thorax 1968:23:356-369.
40. Werkhaven J, Holinger LD. Bronchial casts in children. Ann Otol Rhinol Laryngol 1987;96:86-92.
41. Languepin J, Scheinmann P, Mahut B, et al. Bronchial casts in children with cardiopathies: the role of pulmonary lymphatic abnormalities. Pediatr Pulmonol 1999;28:329-336.
42. Esterl D. Bronchitis fibrinosa bei einem Kind [Fibrinous bronchitis in a child; author's translation]. Z Erkr Atmungsorgane 1978;150:98-100.
43. Suez D, Szefier SJ. Excessive accumulation of mucus in children with asthma: a potential role for erythromycin? A case discussion. J Allergy Clin Immunol 1986;77:330-334.
44. Charman J, Reid L. Sputum viscosity in chronic bronchitis, bronchiectasis, asthma and cystic fibrosis. Biorheology 1972;9:185-199.
45. Shimura S, Sasaki T, Sasaki H, Takishima T, Umeya K. Viscoelastic properties of bronchorrhoea sputum in bronchial asthmatics. Biorheology 1988;25:173-179.
46. Konradova V, Vavrova V, Sulova J. Comparison of the effect of three oral mucolytics on the ultrastructure of the tracheal epithelium in rabbits. Respiration 1985;48:50-57.
47. Ordonez CL, Khashayar R, Wong HH, et al. Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression. Am J Respir Crit Care Med 2001;163:517-523.
48. Field WE. Mucous gland hypertrophy in babies and children aged 15 years or less. Br J Dis Chest 1968;62:11-18.
49. Matsuba K, Thurlbeck WM. A morphometric study of bronchial and bronchiolar walls in children. Am Rev Respir Dis 1972;105:908-913.
50. Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM. Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1304-1309.
51. Djukanovic R. Airway inflammation in asthma and its consequences: implications for treatment in children and adults. J Allergy Clin Immunol 2002;109:539-548.
52. Sheehan JK, Richardson PS, Fung DC, Howard M, Thornton DJ. Analysis of respiratory mucus glycoproteins in asthma: a detailed study from a patient who died in status asthmaticus. Am J Respir Cell Mol Biol 1995;13:748-756.
53. Rubin BK, Ramirez O, Zayas JG, Finegan B, King M. Collection and analysis of respiratory mucus from subjects without lung disease. Am Rev Respir Dis 1990;141:1040-1043.
54. Kauffman HF, Tomee JF, Van Der Werf TS, de Monchy JG, Koeter GK. Review of fungus-induced asthmatic reactions. Am J Respir Crit Care Med 1995;151:2109-2115.
55. Chetty A. Pathology of allergic bronchopulmonary aspergillosis. Front Biosci 2003;8:110-114.
56. Christensen WN, Hutchins GM. Hypereosinophilic mucoid impaction of bronchi in two children under two years of age. Pediatr Pulmonol 1985;1:278-280.
57. Michalski JC, Klein A. Glycoprotein lysosomal storage disorders: alpha- and beta-mannosidosis, fucosidosis and alpha-N-acetylgalactosaminidase deficiency. Biochim Biophys Acta 1999;1455:69-84.
58. Rubin BK, MacLeod PM, Sturgess J, King M. Recurrent respiratory infections in a child with fucosidosis: is the mucus too thin for effective transport? Pediatr Pulmonol 1991;10:304-309.
59. Callahan CW, Redding GJ. Bronchiectasis in children: orphan disease or persistent problem? Pediatr Pulmonol 2002;33:492-496.
60. Biggart E, Bush A. Antiasthmatic drug delivery in children. Paediatr Drugs 2002;4:85-93.
61. Rubin BK, Fink JB. Aerosol therapy for children. Respir Care Clin North Am 2001;7:175-213.
62. Oberwaldner B. Physiotherapy for airway clearance in paediatrics. Eur Respir J 2000;15:196-204.
63. National Asthma Education and Prevention Program. Long-term management of asthma in children: effectiveness of inhaled corticosteroids compared to other medications. J Allergy Clin Immunol [Suppl] 2002;110:147-160.
64. Kai H, Yoshitake K, Hisatsune A, et al. Dexamethasone suppresses mucus production and MUC-2 and MUC-5AC gene expression by NCI-H292 cells. Am J Physiol 1996;271:L484-L488.
65. Rogers DF. Airway goblet cells: responsive and adaptable frontline defenders. Eur Respir J 1994;7:1690-1706.
66. National Asthma Education and Prevention Program. Long-term management of asthma in children: safety of inhaled corticosteroids. J Allergy Clin Immunol 2002;110:160-168.
67. Allen DB. Safety of inhaled corticosteroids in children. Pediatr Pulmonol 2002;33:208-220.
68. Dent G. Ciclesonide (Byk Gulden). Curr Opin Invest Drugs 2002;3:78-83.
69. Everard ML, Bara A, Kurian M, Elliott TM, Ducharme F. Anticholinergic drugs for wheeze in children under the age of two years. Cochrane Database Syst Rev 2002; CD001279.
70. Rogers DF. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol 2002;2:249-255.
71. Ramnarine SI, Haddad EB, Khawaja AM, Mak JC, Rogers DF. On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physiol [Lond] 1996;494:577-586.
72. Nakaya M, Yuasa T, Usui N. Immunohistochemical localization of subtypes of muscarinic receptors in human inferior turbinate mucosa. Ann Otol Rhinol Laryngol 2002;111:593-597.
73. Pavia D, Sutton PP, Lopez-Vidriero MT, Agnew JE, Clarke SW. Drug effects on mucociliary function. Eur J Respir Dis [Suppl] 1983;128:304-317.
74. Hvizdos KM, Goa KL, Tiotropium bromide. Drugs 2002;62:1195-1203.
75. Liu YC, Khawaja AM, Rogers DE Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol 1998;124:563-571.
76. Muijsers RB. Noble S. Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age. Paediatr Drugs 2002;4:123-139.
77. Rubin BK. The pharmacologic approach to airway clearance: mucoactive agents. Respir Care 2002;47:818-822.
78. Rogers DE Mucoactive drugs for asthma and COPD: any place in therapy? Expert Opin Invest Drugs 2002;11:15-35.
79. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001;31:464-473.
80. National Heart, Lung and Blood Institute. World Health Organisation. Global initiative for chronic obstructive lung disease. Publication no. 2701. Bethesda, MD: National Institutes of Health; 2001.
81. Durward A, Forte V. Shemie SD. Resolution of mucus plugging and atelectasis after intratracheal rhDNase therapy in a mechanically ventilated child with refractory status asthmaticus. Crit Care Med 2000;28:560-562.
82. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br Med J [Clin Res] 2001;322:1271-1274.
83. Wright DT, Fischer BM, Li C, Rochelle LG, Akley NJ, Adler KB. Oxidant stress stimulates mucin secretion and PLC in airway epithelium via a nitric oxide-dependent mechanism. Am J Physiol 1996;271:854-861.
84. Rogers DF. Neurogenic inflamation in lung disease: burnt out? Inflammopharmacology 1997;5:319-329.
85. Rogers DF. Tachykinin receptor antagonists for asthma and COPD, Expert Opin Ther Patents 2001;11:1097-1121.
86. Spicuzza L, Haddad EB, Birrell M, et al. Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves. Br J Pharmacol 2000;130:1720-1726.
87. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001;24:487-517.
88. Wills-Karp M. Trophic slime, allergic slime. Am J Respir Cell Mol Biol 2000;22:637-639.
89. Levine SJ, Larivee P, Logun C, Angus CW, Ognibene FP, Shelhamer JH. Tumor necrosis factor-alpha induces mucin hypersecretion and MUC-2 gene expression by human airway epithelial cells. Am J Respir Cell Mol Biol 1995;12:196-204.
90. Shim JJ, Dabbagh K, Takeyama K, et al. Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice. J Allergy Clin Immunol 2000;105:739-745.
91. Torphy TJ, Page C. Phosphodiesterases: the journey towards therapeutics. Trends Pharmacol Sci 2000;21:157-159.
92. Kanehiro A, Ikemura T, Makela MJ, et al. Inhibition of phosphodiesterase 4 attermates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 2001;163:173-184.
93. Li Y, Martin LD, Spizz G, Adler KB. MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro. J Biol Chem 2001:276:40982-40990.
94. Lee HM, Malm L, Dabbagh K, et al. Epidermal growth factor receptor signaling mediates regranulation of rat nasal goblet cells. J Allergy Clin Immunol 2001;107:1046-1050.
95. Nadel JA, Burgel PR. The role of epidermal growth factor in mucus production. Curr Opin Pharmacol 2001;1:254-258.
96. Sommerhoff CP, Caughey GH, Finkbeiner WE, Lazarus SC, Basbaum CB, Nadel JA. Mast cell chymase. A potent secretagogue for airway gland serous cells. J Immunol 1989;142:2450-2456.
97. Sommerhoff CP, Nadel JA, Basbaum CB, Caughey GH. Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cells. J Clin Invest 1990;85:682-689.
98. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, et al. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Respir Cell Mol Biol 1999;20:729-736.
99. Nogami H, Aizawa H, Matsumoto K, et al. Neutrophil elastase inhibitor, ONO-5046 suppresses ozone-induced airway mucus hypersecretion in guinea pigs. Eur J Pharmacol 2000;390:197-202.
100. Shimura S, Sasaki T, Nagaki M, Takishima T, Shirato K. Extracellular ATP regulation of feline tracheal submucosal gland secretion. Am J Physiol 1994:267:159-164.
101. Roger P. Gascard JP, Bara J, de Montpreville VT, Yeadon M, Brink C. ATP induced MUC5AC release from human airways in vitro. Mediators Inflamm 2000;9:277-284.
102. Pendergast WER. P2Y receptor agonists. In: Hansel TT, Bames PJ, editors. New drugs for asthma, allergy and COPD. Basel: Karger AG; 2001. p 165-168.
103. Goswami SK, Kivity S, Marom Z. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro. Am Rev Respir Dis 1990;141:72-78.
104. Gorrini M, Lupi A, Viglio S, et al. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol 2001;25:492-499.
105. Rose MC, Nickola TJ, Voynow JA. Airway mucus obstruction: mucin glycoproteins, MUC gene regulation and goblet cell hyperplasia. Am J Respir Cell Mol Biol 2001;25:533-537.
106. Wang B, Lim DJ, Han J, Kim YS, Basbaum CB, Li JD. Novel cytoplasmic proteins of nontypeable Haemophilus influenzae up-regulate human MUC5AC mucin transcription via a positive p38 mitogen-activated protein kinase pathway and a negative phosphoinositide 3-kinase-Akt pathway. J Biol Chem 2002, 277:949-957.
107. Nakanishi A, Morita S, Iwashita H, et al. Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma. Proc Natl Acad Sci USA 2001;98:5175-5180.
108. Toda M, Tulic MK, Levitt RC, Hamid Q. A calcium-activated chloride channel (HCLCAI) is strongly related to IL-9 expression and mucus production in bronchial epithelium of patients with asthma. J Allergy Clin Immunol 2002;109:246-250.
109. Tesfaigzi Y., Fischer MJ, Martin AJ, Seagrave J. Bcl-2 in LPS- and allergen-induced hyperplastic mucous cells in airway epithelia of Brown Norway rats. Am J Physiol Lung Cell Mol Physiol 2000;279:1210-1217.
110. Bhattacharyya SN, Manna B, Smiley R, Ashbaugh P, Coutinho R, Kaufman B. Smoke-induced inhalation injury: effects of retinoic acid and antisense oligodeoxynucleotide on stability and differentiated state of the mucociliary epithelium. Inflammation 1998;22:203-214.